Targeting syk in autoimmune rheumatic diseases

Frontiers in Immunology

Volumn 7, Issue MAR, 2016, Pages

  Deng, Guo Min ^a   Kyttaris, Vasileios C ^b   Tsokos, George C ^b  

^a NANJING MEDICAL UNIVERSITY   (China)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Autoimmune disease; Fcgamma receptors; IgG; Syk; Syk inhibitor

Indexed keywords

FOSTAMATINIB; PROTEIN KINASE SYK; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN RECEPTOR 2;

DENDRITIC CELL; DIARRHEA; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; HYPERSENSITIVITY; NEUTROPENIA; PROTEIN EXPRESSION; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SHORT SURVEY; SIGNAL TRANSDUCTION; SOFT TISSUE INFLAMMATION; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIC PURPURA; TISSUE INJURY;

EID: 84964627243     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2016.00078     Document Type: Short Survey

References (61)

1. Kurosaki T, Takata M, Yamanashi Y, Inazu T, Taniguchi T, Yamamoto T, et al. Syk activation by the Src-family tyrosine kinase in the B cell receptor signaling. J Exp Med (1994) 179(5):1725-9. doi: 10.1084/jem.179.5.1725
2. Geahlen RL. Syk and pTyr'd: signaling through the B cell antigen receptor. Biochim Biophys Acta (2009) 1793:1115-27. doi:10.1016/j.bbamcr.2009.03.004
3. Mócsai A, Ruland J, Tybulewicz VL. The SYK tyrosine kinase: a crucial player in diverse biological functions. Nat Rev Immunol (2010) 10:387-402. doi:10.1038/nri2765
4. Liu BA, Jablonowski K, Raina M, Arcé M, Pawson T, Nash PD. The human and mouse complement of SH2 domain proteins establishing the boundaries of phosphotyrosine signaling. Mol Cell (2006) 22:851-68. doi:10.1016/j.molcel.2006.06.001
5. Fütterer K, Wong J, Grucza RA, Chan AC, Waksman G. Structural basis for Syk tyrosine kinase ubiquity in signal transduction pathways revealed by the crystal structure of its regulatory SH2 domains bound to a dually phosphorylated ITAM peptide. J Mol Biol (1998) 281:523-37. doi:10.1006/jmbi.1998.1964
6. Abram CL, Lowell CA. The expanding role for ITAM-based signaling pathways in immune cells. Sci STKE (2007) 377:re2. doi:10.1126/stke.3772007re2
7. Grädler U, Schwarz D, Dresing V, Musil D, Bomke J, Frech M, et al. Structural and biophysical characterization of the Syk activation switch. J Mol Biol (2013) 425:309-33. doi:10.1016/j.jmb.2012.11.007
8. Xue L, Geahlen RL, Tao WA. Identification of direct kinase substrates based on protein kinase assay linked phosphoproteomics. Mol Cell Proteomics (2013) 12:2969-80. doi:10.1074/mcp. O113.027722
9. Yablonski D, Weiss A. Mechanisms of signaling by the hematopoietic-specific adaptor proteins, SLP-76 and LAT and their B cell counterpart, BLNK/SLP-65. Adv Immunol (2001) 79:93-128. doi:10.1016/S0065-2776(01)79003-7
10. LeibundGut-Landmann S, Gross O, Robinson MJ, Osorio F, Slack EC, Tsoni SV, et al. Syk-and CARD9-dependent coupling of innate immunity to the induction of T helper cells that produce interleukin 17. Nat Immunol (2007) 8(6):630-8. doi:10.1038/ni1460
11. Cheng AM, Rowley B, Pao W, Hayday A, Bolen JB, Pawson T. Syk tyrosine kinase required for mouse viability and B-cell development. Nature (1995) 378(6554):303-6. doi:10.1038/378303a0
12. Choi OH, Kim JH, Kinet JP. Calcium mobilization via sphingosine kinase in signalling by the Fc epsilon RI antigen receptor. Nature (1996) 380(6575):634-6. doi:10.1038/380634a0
13. Darby C, Geahlen RL, Schreiber AD. Stimulation of macrophage Fc gamma RIIIA activates the receptor-associated protein tyrosine kinase Syk and induces phosphorylation of multiple proteins including p95Vav and p62/GAP-associated protein. J Immunol (1994) 152(11):5429-37.
14. Reeve JL, Zou W, Liu Y, Maltzman JS, Ross FP, Teitelbaum SL. SLP-76 couples Syk to the osteoclast cytoskeleton. J Immunol (2009) 183(3):1804-12. doi:10.4049/jimmunol.0804206
15. Smith-Garvin JE, Koretzky GA, Jordan MS. T cell activation. Annu Rev Immunol (2009) 27:591-619. doi:10.1146/annurev.immunol.021908.132706
16. Kurosaki T, Hikida M. Tyrosine kinases and their substrates in B lymphocytes. Immunol Rev (2009) 228(1):132-48. doi:10.1111/j.1600-065X.2008.00748.x
17. Sanchez-Mejorada G, Rosales C. Signal transduction by immunoglobulin Fc receptors. J Leukoc Biol (1998) 63:521-33.
18. Van Ziffle JA, Lowell CA. Neutrophil-specific deletion of Syk kinase results in reduced host defense to bacterial infection. Blood (2009) 114:4871-82. doi:10.1182/blood-2009-05-220806
19. Kiefer F, Brumell J, Al-Alawi N, Latour S, Cheng A, Veillette A, et al. The Syk protein tyrosine kinase is essential for Fc receptor signaling in macrophages and neutrophils. Mol Cell Biol (1998) 18:4209-20. doi:10.1128/MCB.18.7.4209
20. Mócsai A, Abram CL, Jakus Z, Hu Y, Lanier LL, Lowell CA. Integrin signaling in neutrophils and macrophages uses adaptors containing immunoreceptor tyrosine-based activation motifs. Nat Immunol (2006) 7:1326-33. doi:10.1038/ni1407
21. Tsokos GC. Systemic lupus erythematosus. N Engl J Med (2011) 365(22):2110-21. doi:10.1056/NEJMra1100359
22. Turner M, Mee PJ, Costello PS, Williams O, Price AA, Duddy LP, et al. Perinatal lethality and a block in the development of B cells in mice lacking the tyrosine kinase p72syk. Nature (1995) 378:298-302. doi:10.1038/378298a0
23. Takata M, Sabe H, Hata A, Inazu T, Homma Y, Nukada T, et al. Tyrosine kinases Lyn and Syk regulate B cell receptor-coupled Ca2+ mobilization through distinct pathways. EMBO J (1994) 13:1341-9.
24. Moulton VR, Tsokos GC. Abnormalities of T cell signaling in systemic lupus erythematosus. Arthritis Res Ther (2011) 13:207. doi:10.1186/ar3251
25. Grammatikos AP, Ghosh D, Devlin A, Kyttaris VC, Tsokos GC. Spleen tyrosine kinase (Syk) regulates systemic lupus erythematosus (SLE) T cell signaling. PLoS One (2013) 8:e74550. doi:10.1371/journal.pone.0074550
26. Deane KD, El-Gabalawy H. Pathogenesis and prevention of rheumatic disease: focus on preclinical RA and SLE. Nat Rev Rheumatol (2014) 10(4):212-28. doi:10.1038/nrrheum.2014.6
27. Yamada H, Nakashima Y, Okazaki K, Mawatari T, Fukushi JI, Kaibara N, et al. Th1 but not Th17 cells predominate in the joints of patients with rheumatoid arthritis. Ann Rheum Dis (2008) 67:1299-304. doi:10.1136/ard.2007.080341
28. Sato K. Th17 cells and rheumatoid arthritis-from the standpoint of osteoclast differentiation. Allergol Int (2008) 57:109-14. doi:10.2332/allergolint. R-07-158
29. Crotty S. Follicular helper CD4 T cells (TFH). Annu Rev Immunol (2011) 29:621-63. doi:10.1146/annurev-immunol-031210-101400
30. Wang J, Shan Y, Jiang Z, Feng J, Li C, Ma L, et al. High frequencies of activated B cells and follicular helper T cells are correlated with disease activity in patients with new onset rheumatoid arthritis. Clin Exp Immunol (2013) 174:212-20. doi:10.1111/cei.12162
31. Iwata S, Nakayamada S, Fukuyo S, Kubo S, Yunoue N, Wang SP, et al. Activation of Syk in peripheral blood B cells in patients with rheumatoid arthritis: a potential target for abatacept therapy. Arthritis Rheumatol (2015) 67(1):63-73. doi:10.1002/art.38895
32. Díaz de Ståhl T, Andrén M, Martinsson P, Verbeek JS, Kleinau S. Expression of FcgammaRIII is required for development of collagen-induced arthritis. Eur J Immunol (2002) 32:2915-22. doi:10.1002/1521-4141(2002010)32:10<2915::AID-IMMU2915>3.0.CO;2-4
33. Jakus Z, Simon E, Balázs B, Mócsai A. Genetic deficiency of Syk protects mice from autoantibody-induced arthritis. Arthritis Rheum (2010) 62:1899-910. doi:10.1002/art.27438
34. Elliott ER, Van Ziffle JA, Scapini P, Sullivan BM, Locksley RM, Lowell CA. Deletion of Syk in neutrophils prevents immune complex arthritis. J Immunol (2011) 187:4319-30. doi:10.4049/jimmunol.1100341
35. Huang ZY, Kim MK, Kim-Han TH, Indik ZK, Schreiber AD. Effect of locally administered Syk siRNA on allergen-induced arthritis and asthma. Mol Immunol (2013) 53:52-9. doi:10.1016/j.molimm.2012.06.011
36. Boren JC, Radstake TR, Rossato M. The role of genetics and epigenetics in the pathogenesis of systemic sclerosis. Nat Rev Rheumatol (2014) 10:671-81. doi:10.1038/nrrheum.2014.128
37. Pamuk ON, Can G, Awaz S, Karaca T, Pamuk GE, Demirtas S, et al. Spleen tyrosine kinase (Syk) inhibitor fostamatinib limits tissue damage and fibrosis in a bleomycin-induced scleroderma mouse model. Clin Exp Rheumatol (2015) 33:S15-22.
38. Reilly MP, Sinha U, André P, Taylor SM, Pak Y, Deguzman FR, et al. PRT-060318, a novel Syk inhibitor, prevents heparin-induced thrombocytopenia and thrombosis in a transgenic mouse model. Blood (2011) 117:2241-6. doi:10.1182/blood-2010-03-274969
39. Podolanczuk A, Lazarus AH, Crow AR, Grossbard E, Bussel JB. Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk. Blood (2009) 113:3154-60. doi:10.1182/blood-2008-07-166439
40. Braselmann S, Taylor V, Zhao H, Wang S, Sylvain C, Baluom M, et al. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation. J Pharmacol Exp Ther (2006) 319(3):998-1008. doi:10.1124/jpet.106.109058
41. Cha HS, Boyle DL, Inoue T, Schoot R, Tak PP, Pine P, et al. A novel spleen tyrosine kinase inhibitor blocks c-Jun N-terminal kinase-mediated gene expression in synoviocytes. J Pharmacol Exp Ther (2006) 317(2):571-8. doi:10.1124/jpet.105.097436
42. Sheridan C. Small molecule challenges dominance of TNF-alpha inhibitors. Nat Biotechnol (2008) 26(2):143-4. doi:10.1038/nbt0208-143
43. Pine PR, Chang B, Schoettler N, Banquerigo ML, Wang S, Lau A, et al. Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor. Clin Immunol (2007) 124:244-57. doi:10.1016/j.clim.2007.03.543
44. Coffey G, DeGuzman F, Inagaki M, Pak Y, Delaney SM, Ives D, et al. Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis. J Pharmacol Exp Ther (2012) 340:350-9. doi:10.1124/jpet.111.188441
45. Weinblatt ME, Kavanaugh A, Burgos-Vargas R, Dikranian AH, Medrano-Ramirez G, Morales-Torres JL, et al. Treatment of rheumatoid arthritis with a Syk inhibitor: a twelve week, randomized, placebo-controlled trial. Arthritis Rheum (2008) 58:3309-18. doi:10.1002/art.23992
46. Genovese MC, Kavanaugh A, Weinblatt ME, Peterfy C, DiCarlo J, White ML, et al. An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three month randomized, placebo controlled phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents. Arthritis Rheum (2011) 63:337-45. doi:10.1002/art.30114
47. Deng GM, Liu L, Kyttaris VC, Tsokos GC. Lupus serum IgG induces skin inflammation through the TNFR1 signaling pathway. J Immunol (2010) 184(12):7154-61. doi:10.4049/jimmunol.0902514
48. Deng GM, Liu L, Bahjat FR, Pine PR, Tsokos GC. Suppression of skin and kidney disease by inhibition of spleen tyrosine kinase in lupus-prone mice. Arthritis Rheum (2010) 62:2086-92. doi:10.1002/art.27452
49. Bahjat FR, Pine PR, Reitsma A, Cassafer G, Baluom M, Grillo S, et al. An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus. Arthritis Rheum (2008) 58:1433-44. doi:10.1002/art.23428
50. Weinblatt ME, Kavanaugh A, Genovese MC, Musser TK, Grossbard EB, Magilavy DB. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N Engl J Med (2010) 363:1303-12. doi:10.1056/NEJMoa1000500
51. Okamoto H, Kobayashi A. Spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N Engl J Med (2011) 364:83-4. doi:10.1056/NEJMc1012187
52. Kazerounian S, Duquette M, Reyes MA, Lawler JT, Song K, Perruzzi C, et al. Priming of the vascular endothelial growth factor signaling pathway by thrombospondin-1, CD36, and spleen tyrosine kinase. Blood (2011) 117:4658-66. doi:10.1182/blood-2010-09-305284
53. Tew JG, Wu J, Fakher M, Szakal AK, Qin D. Follicular dendritic cells: beyond the necessity of T-cell help. Trends Immunol (2001) 22:361-7. doi:10.1016/S1471-4906(01)01942-1
54. EI Shikh ME, El Sayed R, Szakal AK, Tew JG. Follicular dendritic cell (FDC)-FcgammaRIIB engagement via immune complexes induces the activated FDC phenotype associated with secondary follicle development. Eur J Immunol (2006) 36:2715-24. doi:10.1002/eji.200636122
55. Aloisi F, Pujol-Borrell R. Lymphoid neogenesis in chronic inflammatory diseases. Nat Rev Immunol (2006) 6:205-17. doi:10.1038/nri1786
56. Manzo A, Bombardieri M, Humby F, Pitzalis C. Secondary and ectopic lymphoid tissue responses in rheumatoid arthritis: from inflammation to autoimmunity and tissue damage/remodeling. Immunol Rev (2010) 233:267-85. doi:10.1111/j.0105-2896.2009.00861.x
57. Anolik JH, Ravikumar R, Barnard J, Owen T, Almudevar A, Milner EC, et al. Cutting edge: anti-tumor necrosis factor therapy in rheumatoid arthritis inhibits memory B lymphocytes via effects on lymphoid germinal centers and follicular dendritic cell networks. J Immunol (2008) 180:688-92. doi:10.4049/jimmunol.180.2.688
58. Victoratos P, Kollias G. Induction of autoantibody-mediated spontaneous arthritis critically depends on follicular dendritic cells. Immunity (2009) 30:130-42. doi:10.1016/j.immuni.2008.10.019
59. Humby F, Bombardieri M, Manzo A, Kelly S, Blades MC, Kirkham B, et al. Ectopic lymphoid structures support ongoing production of class-switched autoantibodies in rheumatoid synovium. PLoS Med (2009) 6:e1. doi:10.1371/journal.pmed.0060001
60. EI Shikh ME, El Sayed RM, Sukumar S, Szakal AK, Tew JG. Activation of B cells by antigens on follicular dendritic cells. Trends Immunol (2010) 31:205-11. doi:10.1016/j.it.2010.03.002
61. Catalan D, Aravena O, Sabugo F, Wurmann P, Soto L, Kalergis AM, et al. B cells from rheumatoid arthritis patients show important alterations in the expression of CD86 and FcgammaRIIb, which are modulated by anti-tumor necrosis factor therapy. Arthritis Res Ther (2010) 12:R68. doi:10.1186/ar2985